Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

Palvella Therapeutics’ drug candidate QTORIN rapamycin receives US patent: Wayne, Pennsylvania Saturday, June 21, 2025, 13:00 Hrs [IST] Palvella Therapeutics Inc, a clinical-sta ...

Moleculin Biotech gets US FDA positive feedback on paediatric study plan for Annamycin in children with R/R AML: Houston Saturday, June 21, 2025, 15:00 Hrs [IST] Moleculin Biotech ...

Virtual webinar on June 23, 2025 at 8:00 am ETNEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated ...

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

The Motley Fool. DATE Tuesday, June 17, 2025, at 4:30 p.m. EDT CALL PARTICIPANTS Chairman and Chief Executive Officer — ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

FDA approves Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in ...

Lucy Hale, Troian Bellisario, Ashley Benson, Shay Mitchell, Sasha Pieterse, Ian Harding, Tyler Blackburn, Keegan Allen and ...

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host ...

Capricor Therapeutics (CAPR) announced four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne ...